Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Estianeptine

Add links
From Wikipedia, the free encyclopedia
Estianeptine
Clinical data
Other names(S)-Tianeptine; S-Tianeptine; TNX-4300; TNX4300
Routes of
administration		Oral[1]
Drug classPeroxisome proliferator-activated receptor (PPAR) agonist; PPARβ/δ and PPARγ agonist
Identifiers
  • 7-[[(11S)-3-chloro-6-methyl-5,5-dioxo-11H-benzo[c][2,1]benzothiazepin-11-yl]amino]heptanoic acid
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC21H25ClN2O4S
Molar mass436.95 g·mol−1
3D model (JSmol)
  • CN1C2=CC=CC=C2[C@@H](C3=C(S1(=O)=O)C=C(C=C3)Cl)NCCCCCCC(=O)O
  • InChI=1S/C21H25ClN2O4S/c1-24-18-9-6-5-8-16(18)21(23-13-7-3-2-4-10-20(25)26)17-12-11-15(22)14-19(17)29(24,27)28/h5-6,8-9,11-12,14,21,23H,2-4,7,10,13H2,1H3,(H,25,26)/t21-/m0/s1
  • Key:JICJBGPOMZQUBB-NRFANRHFSA-N

Estianeptine, also known as (S)-tianeptine and by its developmental code name TNX-4300, is a peroxisome proliferator-activated receptor (PPAR) agonist and atypical tricyclic antidepressant (TCA) which is under development for the treatment of Alzheimer's disease, bipolar disorders, major depressive disorder, and Parkinson's disease.[1][2][3][4][5] It is taken orally.[1]

The drug is the (S)- enantiomer of the atypical TCA and weak opioid tianeptine.[1][4][5][6] It acts as a selective PPARβ/δ and PPARγ agonist.[1][2][4][7] The drug has been found to promote neuroplasticity in vitro, which is thought to be mediated by its PPAR agonism.[4][7] In addition, it has been found to improve cognition and memory in rodents.[8][9] In contrast to tianeptine and (R)-tianeptine, estianeptine shows no activity as a μ-opioid receptor (MOR) agonist.[1][4][7] Moreover, unlike estianeptine, (R)-tianeptine has no activity as a PPAR agonist.[4][7] It has been proposed that estianeptine, via its PPAR agonism, is responsible for the antidepressant effects of tianeptine, rather than tianeptine's weak MOR agonism that manifests at high doses being responsible.[4][7][10] Tianeptine's PPAR agonism may also be responsible for the drug's anti-inflammatory effects.[7]

Estianeptine was first described in the scientific literature by 1997.[11] It is being developed by Tonix Pharmaceuticals.[1][2][4] As of August 2023, the drug is in the preclinical research stage of development for all indications.[1][2] Tianeptine's PPAR agonism was first described in 2022.[12]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 6 7 8 "Estianeptine - Tonix Pharmaceuticals Holding Corp - AdisInsight". adisinsight.springer.com. Retrieved 4 August 2026.
  2. 1 2 3 4 "Delving into the Latest Updates on Estianeptine with Synapse". Synapse. 8 May 2025. Retrieved 4 August 2026.
  3. ↑ "Estianeptine Drug Profile". Ozmosi. 1 January 1900. Retrieved 4 August 2026.
  4. 1 2 3 4 5 6 7 8 Sullivan GM, Daugherty BL, Hsu DT, Rideout DC, Bavari S, Cho J, Harris H, Fogarty S, Lederman S (8 November 2023). Proposed Mechanism of Tianeptine, a Plastogen Antidepressant in Phase II Development in the United States (PDF). CNS Summit 2023. Vol. 20. Boston, Massachusetts, US: Innovations in Clinical Neuroscience. pp. S23–S23. PMC 10712291. Retrieved 4 August 2026.
  5. 1 2 Aslani S, Nafie J, Wahab MF, Armstrong DW (November 2025). "Tianeptine: enantiomeric separations, structural assignment, and biological interactions". Talanta. 294: 128197. doi:10.1016/j.talanta.2025.128197. PMID 40339337.{{cite journal}}: CS1 maint: article number as page number (link)
  6. ↑ Nishio Y, Lindsley CW, Bender AM (November 2024). "Classics in Chemical Neuroscience: Tianeptine". ACS Chem Neurosci. 15 (21): 3863–3873. doi:10.1021/acschemneuro.4c00519. PMC 11587517. PMID 39382192.
  7. 1 2 3 4 5 6 Sullivan GM, Peters A, Hsu D, Rideout D, Roush T, Daugherty B, Peters P, Lederman S (1 June 2023). A Randomized Placebo-Controlled Multicenter Trial of Monotherapy with TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for Treatment of Major Depressive Disorder (MDD) (PDF). American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting. Miami, Florida.
  8. ↑ BioWorld (25 July 2023). "Rat NOR test results support memory- and cognition-enhancing effects of estianeptine". BioWorld. Retrieved 4 August 2026.
  9. ↑ "Tonix Pharmaceuticals Announces Data Supporting the Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, but not (R)-Tianeptine, in the In Vivo Rat Novel Object Recognition (NOR) Test". Tonix Pharmaceuticals Holding Corp. 24 July 2023. Retrieved 4 August 2026.
  10. ↑ "Tonix Pharmaceuticals Announces Pharmacology and Medicinal Chemistry Results that Reveal the Molecular Mechanism of Action of Tianeptine, the Active Ingredient of TNX-601 ER, in Treating Depression". Tonix Pharmaceuticals Holding Corp. 17 May 2023. Retrieved 4 August 2026.
  11. ↑ Oluyomi AO, Datla KP, Curzon G (March 1997). "Effects of the (+) and (-) enantiomers of the antidepressant drug tianeptine on 5-HTP-induced behaviour". Neuropharmacology. 36 (3): 383–387. doi:10.1016/s0028-3908(97)00016-6. PMID 9175617.
  12. ↑ Helmstädter M, Schierle S, Isigkeit L, Proschak E, Marschner JA, Merk D (September 2022). "Activity Screening of Fatty Acid Mimetic Drugs Identified Nuclear Receptor Agonists". Int J Mol Sci. 23 (17). doi:10.3390/ijms231710070. PMC 9456086. PMID 36077469. Table 1. In vitro activity of FAMs with possibly relevant side-target activity and with potential for SOSA1. [...] Tianeptine: [...] partial PPARδ agonist EC50 = 28 ± 4 µM (43 ± 4% max. act.){{cite journal}}: CS1 maint: unflagged free DOI (link)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Estianeptine&oldid=1367752604"